SCHEMBL20482383

SCHEMBL20482383

COCCCOc1cc(CC2(NC=O)CC(OCc3ccccc3)C2)ccc1OC

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ REN P00797 10/20 0.43
▸ SIGMAR1 Q99720 2/20 0.39
▸ SIRT2 Q8IXJ6 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ SMPD1 P17405 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC8 Q9BY41 1/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ NPY1R P25929 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ NPY2R P49146 1/20 0.38
▸ BCHE P06276 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20482672 0.82 REN (0.46) RENSIGMAR1ALDH1A1SMPD1HDAC1
SCHEMBL20482779 0.82 REN (0.47) RENSIGMAR1SMPD1HDAC1HDAC8
SCHEMBL20482240 0.82 REN (0.41) RENSIGMAR1ALDH1A1KMT2AMEN1
SCHEMBL20482988 0.81 HTR1A (0.40) ALDH1A1KMT2ASMN1; SMN2MEN1SMPD1
SCHEMBL20482607 0.80 REN (0.42) RENSIGMAR1SIRT2
SCHEMBL20482799 0.78 REN (0.39) REN
SCHEMBL20482792 0.77 REN (0.40) RENKMT2ALMNAHTT
SCHEMBL20482885 0.77 KMT2A (0.48) SIRT2ALDH1A1KMT2ASMN1; SMN2MEN1
SCHEMBL20482372 0.77 REN (0.40) RENKMT2AMEN1
SCHEMBL20482692 0.76 KMT2A (0.47) SIRT2ALDH1A1KMT2ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018154466-A1 DIHYDROQUINOLIZINONES AS ANTIVIRALS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-08-30 — — WO disclosed
Send feedback